SciBase Secures Highmark Coverage for Nevisense Skin Diagnostic Tool

The policy change allows dermatologists to report the use of Nevisense under CPT code 0658T for patients aged 18 and older. Highmark deems the technology medically necessary when clinicians evaluate suspicious, atypical pigmented lesions on the trunk or extremities. To qualify, lesions must measure between 2 mm and 20 mm, and melanoma must be included in the formal differential diagnosis.

This decision carries significant weight for the Swedish medical technology firm, which has historically relied on a direct-pay model within the American market. With approximately 6,000 U.S. dermatology clinics identified as potential users, SciBase CEO Pia Renaudin described the milestone as a catalyst for scaling. The coverage extends to all Highmark commercial insured lines and participating self-funded employer groups, supported by NCCN Clinical Practice Guidelines that recognize Electrical Impedance Spectroscopy as a tool for aiding the detection of primary melanoma.